Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Metabolic alkalosis (MA) is the most common acid-base disorder and when it's severe it can have effects on cellular function and contribute to an increase in mortality.
MA is a common complication of heart failure (HF) especially when patients are treated with diuretics, but few studies have analyzed the prevalence of acid-base disorders in patients with HF.
All these studies have shown that MA is more common in patients with HF in more advanced stages and that the use of diuretics increases the prevalence of MA.
The study hypothesis, based on clinical experience and the few data that exist in the scientific literature, is that MA is a frequent analytical disorder in patients admitted for decompensated HF and that its presence entails a worse short-term vital prognosis.
The ALCALOTIC study is an observational cohort and prospective study.
The main objectives of the study are the following:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort of exposed patients (Group 1) | All patients admitted for decompensated HF and presenting MA at the time of admission | ||
| Cohort of unexposed patients (Group 2) | All patients admitted for decompensated HF and who do NOT present MA at the time of admission |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital mortality | In-hospital mortality from all causes | an average of 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality during follow-up | All-cause mortality 30 and 90 days after hospital discharge | Mortality at 30 and 90 days after hospital discharge |
| Re-admission (all cause) during follow-up | Re-admission for all causes 30 and 90 days after hospital discharge |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The patients will be recruited from the Internal Medicine Services of Spanish Hospitals whose researchers are active members of the Working Group on Heart Failure and Atrial Fibrillation of the Spanish Society of Internal Medicine
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Internal Medicine Service, Hospital d'Olot (Girona) | Olot | Girona | 17800 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10665945 | Background | Galla JH. Metabolic alkalosis. J Am Soc Nephrol. 2000 Feb;11(2):369-375. doi: 10.1681/ASN.V112369. No abstract available. | |
| 23481366 | Background | Peixoto AJ, Alpern RJ. Treatment of severe metabolic alkalosis in a patient with congestive heart failure. Am J Kidney Dis. 2013 May;61(5):822-7. doi: 10.1053/j.ajkd.2012.10.028. Epub 2013 Mar 5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Re-admission at 30 and 90 days after hospital discharge |
| Readmission for heart failure during follow-up | Re-admission for heart failure 30 and 90 days after hospital discharge | Readmission for heart failure 30 and 90 days after hospital discharge |
| Lenght of Hospital stay | Lenght of Hospital stay during hospital admission | Lenght of Hospital stay will be determined the day of hospital discharge, an average of 7 days after admission/inclusion |
| 40379935 | Derived | Nunez J, Minana G, Villalonga M, Asenjo M, Carrera M, Epelde F, Gil M, Chivite D, Contra A, Pla X, Casado J, Miro O, de la Espriella R, Testani JM, Trullas JC; ALCALOTIC study investigators. Serum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study. Intern Emerg Med. 2025 Aug;20(5):1399-1409. doi: 10.1007/s11739-025-03961-z. Epub 2025 May 17. |